[1] Bhandare N,Antonelli PJ,Morris CG,et al. Ototoxicity after radiotherapy for head and neck tumors[J].Int J Radiat Oncol Biol Phys,2007,67(2):469-479.DOI:10.1016/j.ijrobp.2006.09.017. [2] Bhandare N,Jackson A,Eisbruch A,et al. Radiation Therapy and Hearing Loss[J].Int J Radiat Oncol Biol Phys,2010,76(3):50-57.DOI:10.1016/j.ijrobp.2009.04.096. [3] Petsuksiri J,Sermsree A,Thephamongkhol K,et al. Sensorineural hearing loss after concurrent chemoradiotherapy in nasopharyngeal cancer patients[J].Radiat Oncol,2011,6(4):5-19.DOI:10.1186/1748-717X-6-19. [4] Pacholke HD,Amdur RJ,Schmalfuss IM,et al. Contouring the middle and inner ear on radiotherapy planning scans[J].Am J Clin Oncol,2005,28(1):143-147.DOI:10.1097/01.coc.0000143847.57027.16. [5] Pan CC,Eisbruch A,Lee JS,et al. Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients[J].Int J Radiat Oncol Biol Phys,2005,61(7):1393-1402.DOI:10.1016/j.ijrobp.2004.08.019. [6] Low WK,Burgess R,Fong KW,et al. Effect of radiotherapy on retrocochlear auditory pathways[J].Laryngoscope,2005,115(9):1823-1826.DOI:10.1097/01.mlg.0000175061.59315.58. [7] Haken RKT,Marks LB,Bentzen SM,et al. Quantitative analyses of normal tissue effects in the clinic (QUANTEC):clinical use[J].Radiother Oncol,2010,98(Suppl 2):S8.DOI:10.1016/S0167-8140(11)71723-6. [8] Kodaira T,Tomita N,Tachibana H,et al. Aichi cancer center initial experience of intensity modulated radiation therapy for nasopharyngeal cancer using helical tomotherapy[J].Int J Radiat Oncol Biol Phys,2009,73(4):1129-1134.DOI:10.1016/j.ijrobp.2008.06.1936. [9] Sun Y,Yu XL,Luo W,et al. Recommendation for a contouring method and atlas of organs at risk in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy[J].Radiother Oncol,2014,110(3):390-397.DOI:10.1016/j.radonc.2013.10.035. [10] Wang J,Chen YY,Tai A,et al. Sensorineural hearing loss after combined intensity modulated radiation therapy and cisplatin-based chemotherapy for nasopharyngeal carcinoma[J].Transl Oncol,2015,8(6):456-462.DOI:10.1016/j.tranon.2015.10.003. [11] 中国鼻咽癌临床分期工作委员会.2010鼻咽癌调强放疗靶区及剂量设计指引专家共识[J].中华放射肿瘤学杂志, 2011,20(4),267-269.DOI:10.3760/cma.j.issn.1004-4221.2011.04.001.Committee on clinical staging of nasopharyngeal carcinoma in China expert consensus on target area and dose design guidelines for 2010 nasopharyngeal carcinoma patients with radiotherapy[J].Chin J Radiat Oncol,2011,20(4):267-269.DOI:10.3760/cma.j.issn.1004-4221.2011.04.001. [12] Lin S,Pan J,Han L,et al. Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy:report on the 3-year outcome of a prospective series[J].Int J Radiat Oncol Biol Phys,2009,75:1071-1078.DOI:10.1016/j.ijrobp.2008.12.015. [13] 潘建基,韩露,张瑜,等.鼻咽癌缩小临床靶体积调强放疗疗效探讨[J].中华放射肿瘤学杂志,2010,19(4):283-287.DOI:10.3760/cma.j.issn.1004-4221.2010.04.001. Pan JJ,Han L,Zhang Y,et al. Impact of reducing clinical target volume on efficacy of intensity modulated radiation therapy for nasopharyngeal carcinoma[J].Chin J Radiat Oncol,2010,19(4):283-287.DOI:10.3760/cma.j.issn.1004-4221.2010.04.001. [14] Hsin CH,Chen TH,Young YH,et al. Comparison of otologic complications between intensity-modulated and two-dimensional radiotherapies in nasopharyngeal carcinoma patients[J].Otolaryngol Head Neck Surg,2010,143(5):662-668.DOI:10.1016/j.otohns.2010.07.012. [15] Chan SH,Ng WT,Kam KL,et al. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma:a longitudinal analysis[J].Int J Radiat Oncol Biol Phys,2009,73(4):1335-1342.DOI:10.1016/j.ijrobp.2008.07.034. [16] Zuur CL,Simis YJ,Lamers EA,et al. Risk factors for hearing loss in patients treated with intensity-modulated radiotherapy for head and neck tumors[J].Int J Radiat Oncol Biol Phys,2009,74(2):490-496.DOI:10.1016/j.ijrobp.2008.08.011. [17] Bhide SA,Harrington KJ,Nutting CM.Otological toxicity after postoperative radiotherapy for parotid tumours[J].Clin Oncol,2007,19(1):77-82.DOI:10.1016/j.clon.2006.11.007. [18] Stavas MJ,Carlson ML,Attia A,et al. Does radiation dose to the vestibule predict change in balance function and patient perceived dizziness following stereotactic radiotherapy for vestibular schwannoma?[J].J Neurol Surg Part B,2014,35(5):565-571.DOI:10.1016/j.amjoto.2014.05.002. [19] Wolden SL,Chen WC,Pfister DG,et al. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer:Update of the Memorial Sloan-Kettering experience[J].Int J Radiat Oncol Biol Phys,2006,64(1):57-62.DOI:10.1016/j.ijrobp.2005.03.057. [20] 郭明,王胜资,吴朝霞,等.IMRT 计划优化参数中听觉器官分区限制剂量研究[J].中华放射肿瘤学杂志,2015,24(4):438-441.DOI:10.3760/ cma.j.issn.1004-4221.2015.04.021. Guo M,Wang SZ,Wu ZX,et al. The research of IMRT plan optimization on dose limitation of sub regional auditory organ[J].Chin J Radiat Oncol,2015,24(4):438-441.DOI:10.3760/cma.j.issn.1004-4221.2015.04.021. [21] 钱建军,孙彦泽,周钢,等.T1-2期鼻咽癌RTOG推荐靶区与中国推荐靶区IMRT计划之间后组颅神经NTCP差异性分析[J].中华放射肿瘤学杂志,2016,25(6):546-551.DOI:10.3760/cma.j.issn.1004-4221.2016.06.000. Qian JJ,Sun YZ,Zhou G,et al. Difference in normal tissue complication probability of lower cranial nerves between target volumes recommended by radiation therapy oncology group and China in intensity-modulated radiotherapy for T1-2 nasopharyngeal carcinoma[J].Chin J Radiat Oncol,2016,25(6):546-551.DOI:10.3760/cma.j.issn.1004-4221.2016.06.000.
2017, Vol. 26 
